If left untreated, metabolic syndrome can lead to an increased risk for diabetes mellitus and cardiovascular disease ? both known risk factors for erectile dysfunction (ED).
Doctor Mom?s admonition, “Don?t peel your apple,” is getting new scientific support from scientists in New York, who are reporting isolation of chemical compounds from apple peel that may be involved in the apple?s beneficial health effects.
Doctors should be seizing the opportunity to lead the fight against chronic illnesses like diabetes and heart disease, according to the next head of the international organization for GPs.
New research into urologic conditions ? such as erectile dysfunction ? indicate that these disorders could be associated with or precursors to more serious conditions, and suggest a need for practitioners to view these diseases in the greater context of total health as opposed to isolated disorders.
Research has shown a connection between erectile dysfunction (ED) and cardiovascular disease (CVD) in men, and has established a need to consider one a precursor to the other.
High levels of LDL cholesterol have been associated with a variety of health concerns, including heart disease and, most recently, prostate cancer.
The U.S. Food and Drug Administration (FDA) is aware of a potential safety issue related to Avandia (rosiglitazone), a drug approved to treat type 2 diabetes.
A new UCLA imaging study reveals how inhaling 100 percent oxygen can harm the brain. The findings fly in the face of national guidelines for resuscitation and urge a new approach adding carbon dioxide to the gas mix to preserve brain function in patients.
Natalie Oake and colleagues report on a meta-analysis of studies that recorded hemorrhages and thromboembolic — blood clot — events in patients taking blood-thinners. Their study shows that half of these events could be prevented by closer monitoring and adjustments of these drugs.
Doctors at UPMC have begun a study using an investigational cardiac device, the VentrAssist? Left Ventricular Assist System (LVAD) to see whether it can be used safely and effectively in patients with end-stage heart failure.